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Electronic data captureUsing sequencing information to guide clinical decision-making requires coordination of a diverse set of people
and activities. In clinical genomics, the process typically includes sample acquisition, template preparation,
genome data generation, analysis to identify and conﬁrm variant alleles, interpretation of clinical signiﬁcance,
and reporting to clinicians. We describe a software application developed within a clinical genomics study, to
support this entire process. The software application tracks patients, samples, genomic results, decisions and
reports across the cohort, monitors progress and sends reminders, and works alongside an electronic data
capture system for the trial's clinical and genomic data. It incorporates systems to read, store, analyze and con-
solidate sequencing results from multiple technologies, and provides a curated knowledge base of tumor muta-
tion frequency (from the COSMIC database) annotatedwith clinical signiﬁcance and drug sensitivity to generate
reports for clinicians. By supporting the entire process, the application provides deep support for clinical decision
making, enabling the generation of relevant guidance in reports for veriﬁcation by an expert panel prior to
forwarding to the treating physician.
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Clinical genomics uses information from an individual patient's
genome to inform clinical decision-making. Trials of clinical genomics
strategies involve multidisciplinary teams implementing complex pro-
cesses spanning patient screening, consent, obtaining and processing
biopsy, blood, and other samples, genomic analysis, veriﬁcation of re-
sults, reviewof the results by an expert panel and return of those results
for decision-making.
We have developed a software application speciﬁcally to support
the use of clinical genomics in personalized medicine. This application
is designed to assist a study team, manage the processes involved in
gathering sequencing data and help experts correlate results with
the clinical literature for reporting to physicians. The system tracks pa-
tients, samples, genomic sequencing information, clinical decisions, and
reports across the cohort, monitors progress and sends reminders, and
works alongside an electronic data capture system for the trial's clinical
and genomic data. It incorporates systems to read, store, analyze and
consolidate sequencing results from multiple technologies, and pro-
vides a curated knowledge base of tumor mutation frequency (from
the COSMIC database [1]) annotated with clinical signiﬁcance and
drug sensitivity to generate reports for clinicians.
This application was developed within the study team for the
genomic pathway strategy, a joint project of Ontario Institute for Cancer
Research and the Princess Margaret Hospital-University Health
Network, Ontario, and described more fully in [2]. The protocol is
summarized diagrammatically in Fig. 1. This was a formative feasibility
study, intended to assess the utility of clinical genomics in cancer
patients with metastatic disease resistant to standard of care, and to
develop standard operating procedures for performing clinicalFig. 1. Overview of the genomic
After [2].genomics routinely. This workwas focused on testing whether targeted
sequencing of solid tumors could be used to identify an appropriate
cancer treatment regime within a short time frame (target 21 days).
To date, 146 patients have participated in this study, which has ana-
lyzed more than 476 tumor samples from metastatic and primary
sites, in two different sequencing laboratories.
There are existing technologies that support parts of this process
(e.g., electronic data capture systems, laboratory information man-
agement systems, cancer genomics knowledge bases, and clinical
reporting systems) but they are not integrated, and in many cases
they are unable to accommodate clinical information that is genomic
in nature. This application is not intended to replace the systems to
manage the clinical study in line with good practice [3], nor to replace
LIMS usage in the laboratories, or existing high-quality cancer genome
portals such as cBio [4], My Cancer Genome [5], and even COSMIC [6].
Instead, by supporting the whole protocol, the application provides
integrated support for clinical decisionmaking, enabling the generation
of relevant guidance in reports for veriﬁcation by an expert panel prior
to forwarding to the treating physician.2. Results
Fig. 2 outlines the architecture of the application. There are three
primary but interlinked components: supporting clinical tracking of
participants and samples across study sites; reading, analyzing, and
harmonizing genomic information and identifying novel mutations;
and supporting expert panel decision-making and reporting with a
variety of publications, databases and other sources of information.
Fig. 3 shows the software in action.pathway strategy protocol.
Fig. 2. An overview of the application architecture; shaded components involve private
data.
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2.1.1. Tracking participants
Clinical trials require tracking of participants through the protocol,
recording progress at key stages [3]. Although this study used a com-
mercial electronic data capture (EDC) system for protocol-based data
recording, a key aspect of this study was formative, to establish theFig. 3. Screen display ostandard operating procedures for a future clinical genomics service.
This required an adaptive ﬂexibility that was outside the convention-
al use of EDC.
To accommodate this, the application provides a simple and ﬂexible
tracking interface, recording key dates and results for the stages shown
in Fig. 1, and the elapsed time since consent. This helped the study team
monitor progress and track feasibility, as a key protocol-deﬁned criteri-
on was to deliver results to the treating physician within 21 days of
consent in at least 90% of cases. Constant tracking of performance
criteria enabled the team to identify process improvements throughout
the study.
A second difference between this application and EDC is that this
system was designed to improve the process, not just record it. At
several points, secure and timely notiﬁcation is needed, particularly
between people who are not physically co-located. To assist with this,
the application automatically generates and sends messages and
reminders— currently using email, although text messaging is planned
asmobile devices are oftenmore appropriate for laboratory-based staff.
The application uses the same notiﬁcation framework to send daily
status updates to core project staff, again to enable easy monitoring.
2.1.2. Tracking samples
The application also tracks samples, associating them with partici-
pant records of the date, site, and other biopsy data as speciﬁed by the
protocol. As each sample is registered, the systemgenerates notiﬁcationf the application.
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laboratories, complementing a LIMS by allowing samples in progress
to be tracked visibly at the study level, and enabling the study coordina-
tor to identify and resolve delays proactively.
2.2. Genomic information management
The second main role of the application is to integrate and manage
sequencing data. This is a challenge given the different technologies
used. The application supports both genotyping and high-throughput
sequencing. Initially, the sequence target overlapped with recurrent
mutations tested using a custom genotyping panel, but the sequence
target is expanding progressively to awider set of genes and potentially
full exome sequencing.
2.2.1. Reading genomic data
The application handles a range of sources of genomic informa-
tion, ranging from genotyping panels through to high-throughput
sequencing, and other speciﬁc assays for CAP/CLIA veriﬁcation. These
are derived from proprietary software (e.g., in the case of Sequenom
[7]) or involvemore open formats, such as VCF [8] or GFF [9]. To accom-
modate this, the application uses a set of genomic information pipeline
plug-ins that read genomic information. Each genomic information
source can provide its own pipeline, allowing new sources to be
added without modifying the application itself. The application man-
ages a registry of pipelines, and offers uploaded genomic information
ﬁles to each matching pipeline until one successfully transforms the
ﬁle into genomic information in a canonical form.
In addition to these pipelines, each information source typically uses
a versioned panel that may change independently of the genomic data
format. The application deﬁnes each panel as a set of targets which
minimally specify a chromosome and genomic coordinate bounds, but
which may also specify expected reference and variant alleles, and
even HGVS-speciﬁed mutations, primarily for genotyping panels.
At various times, the study used Sequenom [7], PacBio RS [10],
Illumina MiSeq, and ABI Sanger analysis techniques. In each case,
the panels were reﬁned to resolve errors and improve the reliability
and range of variants identiﬁed. The component-based data-reading
model made it possible to move from 20 kb targeted across 19
genes with PacBio RS to 95 kb targeted across 50 genes using MiSeq
without making any code changes to the application.
The internal genomic information representation uses a three-
valued logic (yes/no/unknown), allowing unknown results to be distin-
guished from negative results. Combined with the panels, which
provide an auditable record of what was tested in a given sample,
this allows genomic information ﬁles to be relatively brief, omitting
negative results.
2.2.2. Deriving genomic information from genotyping panels
Sequenom provides proprietary software to display its analysis
results [7]. The Sequenom software generates a spreadsheet containing
the observedmutation data. The application provides a Sequenompipe-
line to translate these spreadsheets into internal genomic information.
The Sequenom data plug-in has a number of built-in assumptions.
Sequenom results are based on a speciﬁc NCBI isoform for each
gene. For SNPs, the reported variant allele is valid, but for complex
mutations and indels the variant allele is derived from multiple assays,
and (except where there is an associated refSNP, see [7], p30), the
Sequenom software reports the variant by assay. Unfortunately, many
of these assays are minimally documented. As an example, consider
the EGFR mutation, ‘p.E746_A750del’: Sequenom reports this as:
‘DEL(EGFR_M01F)&DEL(EGFR_M02R)’ indicating deletions detected
by two assays. To resolve this, the plug-in uses the panel deﬁnition as
a look-up table to derive a more accurate variant allele as part of the
complete genomic description of the variant, for example mappingthis to ‘c.2235_2249del’ and ultimately to genomic coordinates and
a variant allele based on the human reference genome — hg19.
2.2.3. Deriving genomic information from high-throughput sequencing
The genome research laboratory in the study has used two different
high-throughput sequencing technologies to sequence the genes of
interest, initially PacBio RS, and more recently Illumina MiSeq. In both
cases, the resulting FASTQ ﬁles from the instruments are aligned
to the human genome using Novoalign (http://www.novocraft.com)
followed by variant calling using the Genome Analysis Toolkit [11]
with standard ﬁltering, annotated with ANNOVAR [12] and translated
into a data ﬁle for submission to the study's software application. Like
ANNOVAR, the reported data determines mutation positions by chro-
mosome and genomic coordinates. An HGVS protein-level mutation
[13,14] is also incorporated in the report data: this is generated by
ANNOVAR. The genomic data for variants is always complete, so the
protein-level mutation is not strictly required, but it does make the
sequencing reports easier to audit. Data from the high-throughput
sequencing systems remains in genomic coordinates throughout, and
is therefore easy to integrate with the augmented mutation references
from Sequenom and Sanger sequencing.
2.2.4. Clinical veriﬁcation
Before reporting, identiﬁed variants were veriﬁed in the CAP/CLIA
lab using an orthogonal technology: Sanger sequencing. The Sanger
sequencing reports are handled similarly to the Sequenom reports.
They include an HGVS-standard variant speciﬁed at the DNA level
along with an NCBI identiﬁed gene variant. The software uses a posi-
tioning component based on the hg19 (GRCh37) reference genome to
calculate genomic coordinates for the mutation, in much the same way
as Mutalyzer [15]. The Sanger reports also include the protein-level
mutation (again in HGVS nomenclature) but as with high-throughput
sequencing, the coding-sequence mutation description is used for
variant speciﬁcation, as it is more precise.
Unknown results are handled differently for clinical veriﬁcation.
Sanger sequencing cannot be used to reliably verify low-frequency
mutations (typically when the mutation is present in less than 30%
of the sample, corresponding to a ratio of mutant to total allele
count of 15%). As speciﬁed by the protocol, the application considers
unveriﬁed results as not reportable.
2.2.5. Concordance between independent variant reports
Once variants have been identiﬁed, the software computes concor-
dance, determining when independent mutation reports refer to the
same mutation. While using genomic coordinates internally reduces
this problem substantially, it doesn't eliminate it entirely as there are
some cases (e.g., deletions across frames) where there may be several
ways of representing the same variant at the nucleotide level. HGVS
nomenclature is not sufﬁcient, and even with genomic coordinates
effective analysis and comparison of mutation reports demand consis-
tency and precision in their interpretation.
Table 1 shows the different features reported from each source. All
mutation reports include the gene and amino-acid mutations, but
neither are used internally, due to their ambiguity compared to the
genomic data. A good example is MET ‘T992I’, which is sometimes
reported as ‘T1010I’ depending on the transcript variant. While in
NM_000245 it is reported as ‘p.T992I’, in NM_001127500 it is
reported as ‘p.T1010I’. Both may occur in the literature, and there-
fore gene and mutation may be ambiguous unless paired with a tran-
script variant reference. To resolve this, positional data from the hg19
reference (the ‘refGene.txt’ data ﬁle, obtained from [16]) is used to
translate the HGVS-standard coding-sequence mutation and the
NCBI identiﬁer into genomic coordinates and a variant allele. This
results in an unambiguous combination (gene, chromosome, genomic
coordinates and variant allele), which can be used to merge mutation
reports from all technologies.
Table 1
Table of features for each mutation report type (P is provided, I is inferred during interpretation). CDS mutations are coding-sequence (nucleotide) mutations; AA mutations are
amino-acid (protein-level) mutations.
Format Chromosome Gene Start Stop Variant allele NCBI id CDS mutation Assay id AA mutation
Sequenom I P I I Pa I P P
Sanger I P I I I P P P
PacBio/MiSeq P P P P P P
a Sequenom's reporting of the variant allele is convoluted, as it reports the variants broken down by each individual assay. Because of this, the reported variant allele is not
congruent with reports from sequencing technologies, and although it is provided, it is replaced by more precise inferred values.
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Once a set of concordant variants are conﬁrmed, the software pro-
vides a set of tools that integrate automatically calculated and manu-
ally curated information into a knowledge base for reporting on each
variant.
2.3.1. Model of mutation signiﬁcance
Each mutation's clinical signiﬁcance is modeled using a variety of
factors, which form the basis for the report. These include whether
it is novel or previously known, and its frequency of association
with different cancer types [6], somatic and germline impact [17],
whether it is believed to be relevant to the patient's cancer, and the
trial type and level of evidence (based on [18]) for both its likely sig-
niﬁcance and treatment options in the clinical literature with
hyperlinked PubMed IDs. This enables description of the wide vari-
ability between mutations, from those which are known to have no
signiﬁcance, through those which are suspected to be relevant due
to their position in a known oncogene, through to those which have
been extensively investigated for prognostic or predictive clinical
effects.
The application integrates clinical information between genomic
and protein levels. Most clinical information references genes and
protein-level variants in traditional nomenclature. Best practice, at
least for reporting, is to provide a HGVS DNA-level description [13]
as well as a protein-level one [14], but this is not common in the clin-
ical literature or in practice [19]. In testing the Open Access subset of
PubMed, we found about 95% of the identiﬁed HGVS sequence variant
references (170,900 out of 178,814) used a protein-level nomencla-
ture rather than a DNA-level one. This is important, as it means ﬁnd-
ing relevant clinical information about a given mutation requires
representation at the protein level, if only to enable effective search
of PubMed. This application, therefore, primarily targets reports at
the protein-level to improve clinical accessibility.
2.3.2. Automatically-derived information: mutation frequencies
Associations between mutations and known tumor types were a
central feature of these reports. The application calculates these
from COSMIC [1], using hg19 (GRCh37) genomic coordinate resolu-
tion to ensure that they are consistent with identiﬁed mutations,
and aggregated to provide mutation frequencies by tumor type. In
some cases, this involved normalizing mutation data that were am-
biguous. Taking the mutation KRAS ‘p.G12V’ as an example, there
are three mutations in COSMIC that share the same protein-level rep-
resentation: COSMIC IDs: 520 (‘c.35G>T’), 515 (‘c.35_36GT>TC’),
and 25879 (‘c.?’, sic). These are pooled to calculate frequencies at
the protein level, and then attached to all corresponding coding
sequence mutations. This is based on the explicit assumption that
coding-sequence variants are less important than amino-acid
variants — at least as far as tumor frequencies are concerned. There
are a number of other aspects to the processing of COSMIC data,
including: clinician-derived recoding of variants in benign types
such as moles; merging duplicate reports for the same variant in a dif-
ferent transcript; and normalizing extremely low-frequency variants.
The script we developed (available at: …) generates an XML ﬁle that
can be loaded through a RESTful API for incremental updates. Notethat this updates report content, so all reports are versioned to ensure
that previously issued reports remain unchanged.
2.3.3. Annotating clinical reports
Once the automatic information has been used to construct an ini-
tial report template for a variant, the application supports an overlay
of manually curated clinical information. Combining automatically-
and manually-derived information in a single report was a design
challenge, with options ranging from a fully structured form based
on the model of signiﬁcance described in Section 2.3.1 above, to a
wiki. Currently, the application provides a structured editable form
that allows clinical information to be modiﬁed while maintaining a
close mapping to the ﬁnal report format. This form also structures
the use of the level of evidence scale [18] and records PubMed IDs
for relevant clinical literature.
To assist with ﬁnding clinically relevant information, the applica-
tion includes a set of search functions linked directly to high-quality
information sources such as PubMed, Google Scholar, COSMIC, and
My Cancer Genome, so that the expert panel could quickly locate rel-
evant information about a variant directly from that variant's report.
2.3.4. Report curation workﬂow
Reports are managed with a workﬂow and approval system, so
that changes are tracked and logged. This is needed for clinical
reports, as additional clinical information may be discovered as the
study progresses. Similarly, databases such as COSMIC used for muta-
tion frequency calculation are in constant growth, so frequencies do
change over time. It is therefore important to record which version
of the report was used for each patient, who approved it and when,
so it can form part of a permanent record. When completed and
approved, the system generates the report and renders it as a signed
and approved PDF ﬁle for archival and transmission purposes. An
example is shown in Fig. 4.
2.4. The expert panel and reporting on variants
Once variants have been identiﬁed and conﬁrmed, the application
provides an integrated view of everything relevant to an individual
participant, shown in Fig. 5. This includes all samples, the status of
any observed mutations, and a brief summary of relevant clinical
information necessary to inform the expert panel in recommending
action related to conﬁrmed mutations.
The application provides a modeled structured form for recording
decisions alongside justiﬁcation by the expert panel. This is based on
the classiﬁcation for each mutation as ‘actionable’, ‘reportable’, or ‘not
reportable’. The protocol deﬁned actionable mutations as “mutations
that support a particular clinical trial or treatment recommendation,
or that have known prognostic or diagnostic implications”. Beyond
this, mutations within genes considered relevant to treatment deci-
sions in patients are reportable, unless it is well established that
they have no clinical signiﬁcance. This excludes synonymous muta-
tions, and a few others, such as MET receptor ‘T992I’/‘T1010I’,
where there is published evidence that the mutation should not inﬂu-
ence treatment decisions. The decision also records the level of
evidence for each variant — this is important to sustainable practice
in the expert panel, as decisions based on a low level of evidence
Fig. 4. Excerpt from a generated mutation report.
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level of evidence.
Because some variants take longer to assess than others, the applica-
tion allows interim reporting, so those with a known function can be
reported quickly while further investigation is conducted to investigate
the possible clinical impact of variants with a less known function.
2.5. Privacy
While there are a number of privacy demands, none of them are un-
usual. The software stores personal medical data: while de-identiﬁed, it
remains coded and is potentially identiﬁable. The system uses a
role-based authorization system, so each user can only access the infor-
mation they need to perform their tasks. Only clinicians and board
certiﬁed laboratory geneticists have access to the clinical data, which
is the most sensitive in regard to patient conﬁdentiality.
3. Discussion
An important design issue across the application was the choice of
representation. Some tasks, such as deriving HGVS nomenclature for
non-SNP variants, and assessing concordance between Sanger
sequencing veriﬁcation and high throughput sequencing, were harder
to automate than they should have been. This has been an active focus
for future work, and an automatic pipeline for this based on SeqWare
[20] is close to completion, using Ensembl's VEP [21] to derive HGVSnomenclature. This matters for a system's ability to integrate into exter-
nal information sources, or even into discussion within a team.
A second design issue was that clinical studies – especially large
multi-center ones – involve complex teams with data and coordina-
tion between people in different roles and different places. Software
can assistwith this, providing transparent status display and automated
notiﬁcations. These issues are not speciﬁc to clinical studies — similar
concerns are apparent in distributed software development. Initially,
the main coordination problems involved communication between
separate laboratories, but this was easy to resolve through automated
email notiﬁcation. As the study grew, however, the problems became
more subtle, and we focused again on the effort involved in translating
genomic information into reports. Automation, again, is central to
addressing this problem, alongside integration with existing LIMS and
analysis pipelines.
The third issue concerned the knowledge gap between mutations
and clinically-relevant reports. The study has moved into a second
stage where the scale of the high-throughput sequencing data is
growing rapidly. Initially using PacBio, the study targeted 60 regions
of 19 genes, each typically 300–400 base pairs, which encompassed
the mutations on the OncoCarta v1.0 panel. Currently, we have scaled
this up to around 100 kb around 50 genes, using MiSeq. This results in
many more mutations being identiﬁed, often of unknown signiﬁ-
cance, lengthening the time to verify, interpret and report the results.
This has increased the strain on the turnaround time. To make sense
of these mutations clinically, more knowledge is required. We are
now working to enrich and automate the annotation, using tools
Fig. 5. Summary view for an individual participant.
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the knowledge base. Using SIFT and similar tools can provide weak
estimation of the functional signiﬁcance of unknown and novel muta-
tions, and using ANNOVAR will enable more uniform processes for
using external mutation databases.
We are also looking into reducing this knowledge gap through
text mining. There is a substantial body of evidence in sources such
as PubMed — the challenge is to make it relevant to each report.
Currently, each report's use of literature involves manual searching
(with tools to help prepare queries). This burdens the experts with
collating the information. There is considerable prior work in this
ﬁeld (e.g., [24]), aimed at reducing the effort needed to prepare a
report by automatically preparing a candidate list of potentially rele-
vant information for the experts.
To date, we have focused onmutations, as set by the study protocol.
Increasingly, we are looking at other types of genomically-identiﬁable
variants, including: translocations, gene fusions, copy number varia-
tions, and methylation. To support these, we are developing variant
representations that accommodate these, and enable the very different
mechanisms needed to identify and report relevant information from
databases and the clinical literature.
These changes will form the basis for a revised and more open ver-
sion of the application, called Heliotrope. This involves (a) generalizing
the data model to support multiple studies using different standard
operating procedures simultaneously, (b) improving the software
architecture to enable scalable performance, advanced data mining,
and a better interface— especially for mobile devices, and (c) widening
the range of automatic data sources available for clinical reporting.
4. Materials and methods
The application is open source in its entirety, built using the Grails
web application framework, and is available at: https://github.com/
oicr-ibc/gps. There are a number of additional components developedusing other technologies. The parser package used to read sequencing
data ﬁles is written in Java and has a well-deﬁned generic interface —
this allows different sequencing ﬁle formats to be accommodated
without changing the main web application. Authentication is based
on the Lightweight Directory Access Protocol (LDAP), allowing easy
deployment and high security within an organization's infrastructure.
The deployed application is a standard Java servlet web archive
(‘WAR’) ﬁle capable of being deployed in any compliant servlet contain-
er. However, for easy deployment, the application's Maven-based build
process can also construct a Debian standard package with an embed-
ded and conﬁgured Jetty web server. This enables single-click deploy-
ment on Debian-based systems. Both Oracle and OpenJDK runtimes
are supported.
Clinical reports are rendered into PDF using the Apache Formatting
Objects Processor (Apache FOP), using theW3CXSL Formatting Objects
standard, using a layout template and data retrieved from the web
application in XML format. This means the report is easy to customize,
both in layout and in content.
The genotyping and sequencing panels are deﬁned using comma-
separated value ﬁles. For sequencing, these ﬁles deﬁne the targeted
genomic coordinate ranges within each chromosome. For genotyping,
these ﬁles also deﬁne the reference and variant alleles used by the
system to validate reported variants. New panels – and new versions
of existing panels – can be added at any time through a RESTful API.
Sequencing reports generated as Excel ﬁles are read using the Apache
POI library. The web application generates spreadsheet-based reports
as Excel-compatible XML ﬁles; the administration interface enables
custom reporting through registered database queries.
We prepared the Sequenom panel data using a conceptually simple,
if laborious, process of identifying themutations tested by the Sequenom
panel, which is proprietary, using GRCh37 as a reference template.
In the process, we discovered that several mutations in OncoCarta
v1.0 have incorrect protein-level descriptions, e.g. ‘L747_T750del’
should be ‘L747_A750del’, while others use inconsistent forms of
147S. Watt et al. / Genomics 102 (2013) 140–147traditional representation, e.g. ‘E746_T751del,I ins’ should be
‘p.E746_T751>I’. Since the genomic coordinate system makes
these unambiguous, we prepared an accurate and complete descrip-
tion for the OncoCarta v1.0 panel using canonical genomic repre-
sentations for all mutations. This panel deﬁnition is available at:
http://git.io/ioSw9Q.
The knowledge base depends on a re-processing of the data in
COSMIC that is implemented by a Perl script which transforms the
COSMIC export data into an XML ﬁle of frequency information by
canonical gene transcript and protein-level mutation, available at:
http://git.io/SJd4dA. This XML ﬁle is imported into the application
through the same RESTful API used for genotyping and sequencing
panels. A number of other Perl scripts are available in the same location;
these provided the analysis of references to DNA-level and protein-level
variants in PubMed by publication year, used to generate the data
discussed in Section 2.3.1.Acknowledgments
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